产品
编 号：F749988
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2226775-26-2
产品详情
生物活性：
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas.
体内研究：
Tilvestamab (30 mg/kg; i.p.; twice a week) suppresses tumor growth by inhibiting AXL in orthotopic RCC model.Animal Model:Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model).
Dosage:30 mg/kg
Administration:Intraperitoneal injection; twice a week
Result:Significantly inhibited RCC growth down to about 1/3 of the volume.
体外研究：
Tilvestamab (250 μM; 1 h) inhibits AXL phosphorylation in 786-0 cells.
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas.
体内研究：
Tilvestamab (30 mg/kg; i.p.; twice a week) suppresses tumor growth by inhibiting AXL in orthotopic RCC model.Animal Model:Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model).
Dosage:30 mg/kg
Administration:Intraperitoneal injection; twice a week
Result:Significantly inhibited RCC growth down to about 1/3 of the volume.
体外研究：
Tilvestamab (250 μM; 1 h) inhibits AXL phosphorylation in 786-0 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备